There’s a tsunami on the horizon, and it has cancer “running scared.” Those were the words from Fred Hutchinson Cancer Research president Dr. Gary Gilliland, who spoke Tuesday at the… Read More
Juno Therapeutics is no stranger to huge financing deals. The Seattle biotech company, which emerged on the scene just two years ago, raised $314 million in venture capital financing before… Read More
Shares of Seattle-based biotech startup Juno Therapeutics spiked more than 60 percent in after-hours trading on Monday after the company announced a $1 billion investment from Celgene. The 10-year “collaboration” will… Read More
Shares of Juno Therapeutics jumped more than six percent on Tuesday after the Seattle biotechnology company announced its acquisition of Waltham, Massachusetts-based X-BODY Inc. X-BODY is small, employing just nine… Read More
The largest independent nonprofit in the U.S. focused solely on infectious disease research is changing its name to better align with what it does: Seattle BioMed is becoming the Center… Read More
Fast-growing Juno Therapeutics — fresh off its IPO from last December — is expanding its presence in its hometown of Seattle. The company just entered into a lease agreement for… Read More
Dendreon, the once-promising Seattle biotechnology company that developed treatments for prostate cancer, will be sold to Quebec-based Valeant Pharmaceuticals International Inc. after no additional qualified bids emerged in the company’s bankruptcy… Read More
Juno Therapeutics, the fast-growing Seattle biotechnology company, today announced that it plans to open a new manufacturing facility in Bothell for its cell therapy products. The facility will open in… Read More
Adaptive Biotechnologies, a Seattle company that’s working on sequencing to profile T-cell and B-cell receptors, today announced that it is acquiring San Francisco-based Sequenta Inc. The company said in a press… Read More
Cerevast Therapeutics, a 5-year-old Redmond company that’s developing a novel approach for treating stroke patients with ultrasound, has raised $10 million in fresh funding, according to a filing with the SEC.… Read More
Juno Therapeutics, a heavily-funded cancer research company that was formed just 16 months ago, priced its initial public offering Thursday night at $24 per share. That was above the expected… Read More
Fast-moving Juno Therapeutics is moving closer to becoming a publicly-traded company. The Seattle biotechnology company today updated is IPO filing with the SEC, indicating that it plans to price shares… Read More
Seattle’s Fred Hutchinson Cancer Research Center has tapped D. Gary Gilliland, an expert in cancer genetics and former vice president of precision medicine at the University of Pennsylvania’s Perelman School of Medicine, as… Read More
—Startup vet Shauna Causey — a former marketing executive at UP Global and Decide.com — has landed a new gig at Seattle health startup EveryMove. In addition, the company named… Read More
Danish drug maker Novo Nordisk announced plans today to open a new obesity research unit in Seattle, a move that had been previously reported earlier this month. The facility will attempt… Read More
Seattle’s biotech industry has been on an up-and-down roller coaster ride over the past 12 months, with layoffs and R&D center closures as well as huge financing rounds. Now, the… Read More
Seattle has been struck with some tough setbacks in the biotech community in the past few months, including the recent news that Amgen plans to close its R&D center along Elliott… Read More
Here’s another dose of bad news for Seattle’s biotech industry. Novo Nordisk this week announced plans to discontinue R&D efforts related to inflammatory disorders, a move that will cost about… Read More
News that Amgen plans to shutter its 40-acre campus along Elliott Bay marks yet another setback for Seattle’s biotech industry, which has struggled to take root over the years. Amgen… Read More
Accelerator Corp, the Seattle biotechnology investment fund started in Seattle 11 years ago, has raised $51.1 million in capital as part of a first closing of its fourth fund. Accelerator… Read More
Seattle biotechnology company Immune Design, which is working on novel technologies that activate the body’s immune system to fight cancer, set its IPO range at $12 o $14 per share.… Read More
Immune Design Corp., a Seattle biotechnology company developing technologies to activate the body’s immune system to fight cancer, has filed to raise $60 million through an initial public offering. The… Read More
Researchers from Seattle who are finding ways to eliminate cancer are bringing in some serious funding today. On the same day the Fred Hutchinson Cancer Research Center announced a $20 million donation… Read More
Seattle BioMed has received a $9.8 million grant from National Institute of Allergy and Infectious Diseases to fund the initial phases of a vaccine that could neutralize antibodies against HIV-1. The… Read More
NanoString Technologies, a provider of life science tools for research and molecular diagnostic products, has filed to raise $55 million through a secondary stock offering. The filing comes seven months… Read More
One big problem with existing cancer therapies available today like chemotherapy and radiation is the collateral damage. While some medicine can completely kill cancer, it also may destroy healthy, normal… Read More
In one of the largest series A venture capital deals this year in the biotechnology sector, Seattle-based Juno Therapeutics has landed $120 million in startup financing in a deal led… Read More
Blaze Bioscience has raised $9 million in fresh funding from individual investors, money that the Seattle spinoff of the Fred Hutchinson Cancer Research Center will use to continue development on… Read More
Once a rising star in Seattle’s biotechnology community, Dendreon Corp. announced Tuesday that it is reducing its staff by 15 percent in an effort to accelerate a path to profitability… Read More
Immune Design has reeled in $32.5 million in venture capital financing, with plans to raise up to $16.5 million more in the series C round if certain milestones are met.… Read More